Following on from information provided to NICE by the company in May 2022 the appraisal of Amcenestrant for treating oestrogen-receptor positive, HER2-negative advanced breast cancer after hormonal therapy was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 3919 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 May 2023 | Discontinued. Following on from information provided to NICE by the company in May 2022 the appraisal of Amcenestrant for treating oestrogen-receptor positive, HER2-negative advanced breast cancer after hormonal therapy was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 03 May 2022 | Suspended. As you will be aware the Department for Health and Social Care has asked NICE to carry out an appraisal of amcenestrant for treating oestrogen-receptor positive, HER2-negative advanced breast cancer after hormonal therapy. For information, the company have announced that Phase 2 AMEERA-3 did not meet its primary endpoint in patients with locally advanced or metastatic oestrogen receptor positive, human epidermal growth factor 2 negative (ER+/HER2-) breast cancer who progressed on or after hormonal therapies (i.e. second-line advanced breast cancer setting). Therefore they will no longer be pursuing a marketing authorisation application in this indication at this time and NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes |
For further information on our processes and methods, please see our CHTE processes and methods manual